| abstract |
Provided are isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising Glypican-3 antibodies are also disclosed. Method for detecting Glypican-3, as well as methods for treating various Glypican-3 related conditions, including heptacellular cancer, are disclosed. |